Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
| ▸ | GABRD | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.36 |
| ▸ | GABRE | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123758 | 0.86 | NNMT (0.36) | DPP4NNMTGABRPGABRDGABRA1 | |
| SCHEMBL22122764 | 0.81 | HTR1A (0.34) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL25378992 | 0.81 | LMNA (0.40) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4986376 | 0.79 | DPP4 (0.47) | DPP4NNMTPDE4APDE4BPDE4C | |
| SCHEMBL22145148 | 0.79 | NNMT (0.50) | DPP4NNMTPDE4APDE4BPDE4C | |
| SCHEMBL25378442 | 0.79 | NOS3 (0.37) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL25281718 | 0.78 | DPP4 (0.40) | DPP4NNMTPDE4APDE4BPDE4C | |
| SCHEMBL31573387 | 0.78 | RECQL (0.41) | DPP4NNMTPDE4APDE4BPDE4C | |
| SCHEMBL10322295 | 0.78 | DPP4 (0.43) | DPP4NNMTPDE4APDE4BPDE4C | |
| SCHEMBL17161176 | 0.78 | DPP4 (0.40) | DPP4NNMTPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | US | disclosed |
| EP-3898634-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127508-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127508-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| EP-2488530-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-08-09 | — | — | US | disclosed |
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011057382-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | DPP4 677/4885NNMT 3436/4885PDE4A 2302/4885 |
| US-20220144848-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | MVD, VASP, SELP | DPP4 457/4885NNMT 532/4885PDE4A 1050/4885 |
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | DPP4 411/4885NNMT 3700/4885PDE4A 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.